Search - tctmd.com

Displaying 241 - 260 of 342

Sort: Relevancy | Date

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Salvatore Cassese

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Laura Mauri

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2016

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Presenter: Deepak L. Bhatt, Christian W. Hamm

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, John A. Bittl

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

Presentation TCT 2015

Optimal DAPT Duration After DES

Presenter: George D. Dangas, Paul A. Gurbel, Somjot S. Brar

October 13, 2015

Presentation TCT 2015

Acute DAPT Decisions: Agent Selection and Whether to Load

Presenter: George D. Dangas, Paul A. Gurbel

October 13, 2015

Presentation TCT 2015

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Presenter: Eric R. Bates, Spencer B. King III, Daniel I. Simon

October 13, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

Presentation TCT 2015

DAPT Duration Case 2: An Elderly Patient With CKD and Left Main Bifurcation Stenting Postdischarge Course

Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino

October 12, 2015

Advertisement

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Debate: Making the Case for Very Limited Use of Cangrelor!

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Optimal DAPT Duration After DES

Acute DAPT Decisions: Agent Selection and Whether to Load

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

DAPT Duration Case 2: An Elderly Patient With CKD and Left Main Bifurcation Stenting Postdischarge Course

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content